NEED TO KNOW

  • Trump-appointed judge declined to block mail-order mifepristone, stayed the case pending FDA review
  • Same ruling found Louisiana likely to win on the merits — and suffers "irreparable harm" daily
  • Louisiana AG took the fight to the 5th Circuit on April 21 seeking a stay pending appeal

LAFAYETTE, LA (TDR) — A Trump-appointed federal judge refused to immediately block mail-order shipments of the abortion pill mifepristone, then handed Louisiana every legal finding it needs to win on appeal.

The big picture: The decision from U.S. District Judge David Joseph is being read as a Louisiana setback — but the 37-page opinion says the opposite of what the headline suggests.

Freedom-Loving Beachwear by Red Beach Nation - Save 10% With Code RVM10

  • The court found Louisiana has standing to sue
  • The court found Louisiana is "likely to succeed on the merits"
  • The court found Louisiana suffers "irreparable harm every day" the rules remain in effect

Why it matters: The actual decision-maker isn't the judge — it's the FDA, and its review timeline now controls when access could change.

  • Roughly one in four U.S. abortions now happen via telehealth, a fivefold rise since 2022
  • A change to the 2023 dispensing rule reaches every state, including those where abortion remains legal

Driving the news: Joseph's ruling stayed Louisiana's case so the FDA can finish its pending safety review of mifepristone, but he attached conditions that keep pressure on the agency.

CLICK HERE TO READ MORE FROM THE THE DUPREE REPORT

Following ongoing debates over border security and immigration policy in 2026, do you support stricter enforcement measures?

By completing the poll, you agree to receive emails from The Dupree Report, occasional offers from our partners and that you've read and agree to our privacy policy and legal statement.
  • The FDA must update the court within six months
  • The pause is not indefinite — Joseph warned he could rule for Louisiana later
  • Louisiana AG Liz Murrill asked the 5th Circuit on April 21 to stay the rule pending appeal

What they're saying: Both sides claimed the ruling and named what came next.

  • Liz Murrill, Louisiana Attorney General — "Judge Joseph concluded that Louisiana has standing to sue and is likely to succeed in showing that the 2023 REMS is unlawful."
  • Alexis McGill Johnson, Planned Parenthood Federation President — "From the courts to the Trump administration to state legislatures across the country, mifepristone and abortion access are very much still under attack."
  • Julia Kaye, ACLU senior staff attorney — described the stay as preferable to immediate restrictions but warned the Trump administration "now holds the baton" on access.

Yes, but: The ruling isn't a clean win or loss for either side — and it exposes a Republican split on tactics.

  • The Trump administration's DOJ asked the court to pause the case, drawing visible frustration from anti-abortion activists who wanted an immediate ruling
  • Legal historian Mary Ziegler called the dynamic "a kind of civil war between Republicans" over how aggressively to move on mifepristone

Between the lines: Both sides are arguing about a courtroom that won't decide the outcome. The agency review is the actual decision point, and neither side says so publicly because admitting it would shift the political fight from the bench to the FDA — where pressure tactics differ.

  • Anti-abortion advocates need the review to find safety problems, or the case stalls
  • Abortion-rights advocates need the review to validate the 2023 rule, or the case revives with judicial findings already against them

What's next:

If a federal agency's internal review can functionally settle a constitutional question states are litigating, who exactly is making the law?

Sources

This report was compiled using information from NPR, CNN, STAT News, the American Press, The Hayride, Ms. Magazine, and the Georgetown Health Care Litigation Tracker.

Freedom-Loving Beachwear by Red Beach Nation - Save 10% With Code RVM10